Shopping Cart 0
Cart Subtotal
USD 0

Immupharma Plc (IMM) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Immupharma Plc (IMM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company's operations and business divisions.

- Corporate strategy - Analyst's summarization of the company's business strategy.

- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history - Progression of key events associated with the company.

- Major products and services - A list of major products, services and brands of the company.

- Key competitors - A list of key competitors to the company.

- Key employees - A list of the key executives of the company.

- Executive biographies - A brief summary of the executives' employment history.

- Key operational heads - A list of personnel heading key departments/functions.

- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities - A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ImmuPharma Plc (ImmuPharma) develops novel drugs for the treatment of serious medical conditions with unmet medical need. ImmuPharma develops drugs for the treatment of lupus, cancer, moderate to severe pain, highly resistant hospital-acquired infections such as methicillin-resistant staphylococcus aureus infection and inflammatory disorders including rheumatoid arthritis and asthma. The company's product pipeline comprises Lupuzor, for the treatment of Lupus; IPP-204106, for the treatment of cancer; and peptide platform for the treatment of metabolic disorders. It has operations in France and Switzerland. ImmuPharma is headquartered in England, the UK.

Immupharma Plc Key Recent Developments

May 29,2018: ImmuPharma: Final Results Announcement for the twelve months ended 31 December 2017

Sep 27,2017: ImmuPharma: Interim Results Announcement for the Six Months Ended 30 June 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1 - About the Company 5

Immupharma Plc - Key Facts 5

Immupharma Plc - Key Employees 6

Immupharma Plc - Key Employee Biographies 7

Immupharma Plc - Major Products and Services 8

Immupharma Plc - History 9

Immupharma Plc - Company Statement 11

Immupharma Plc - Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Section 2 - Company Analysis 15

Company Overview 15

Immupharma Plc - Business Description 16

Immupharma Plc - Corporate Strategy 17

Immupharma Plc - SWOT Analysis 18

SWOT Analysis - Overview 18

Immupharma Plc - Strengths 18

Immupharma Plc - Weaknesses 19

Immupharma Plc - Opportunities 20

Immupharma Plc - Threats 21

Immupharma Plc - Key Competitors 22

Section 3 - Company Financial Ratios 23

Financial Ratios - Capital Market Ratios 23

Financial Ratios - Annual Ratios 24

Performance Chart 26

Financial Performance 26

Financial Ratios - Interim Ratios 27

Financial Ratios - Ratio Charts 28

Section 4 - Company's Lifesciences Financial Deals and Alliances 29

Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

Immupharma Plc, Recent Deals Summary 31

Section 5 - Company's Recent Developments 32

May 29, 2018: ImmuPharma: Final Results Announcement for the twelve months ended 31 December 2017 32

Sep 27, 2017: ImmuPharma: Interim Results Announcement for the Six Months Ended 30 June 2017 39

Section 6 - Appendix 41

Methodology 41

Ratio Definitions 41

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Immupharma Plc, Performance Chart (2013 - 2017) 26

Immupharma Plc, Ratio Charts 28

Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Immupharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30


List Of Table

List of Tables

Immupharma Plc, Key Facts 5

Immupharma Plc, Key Employees 6

Immupharma Plc, Key Employee Biographies 7

Immupharma Plc, Major Products and Services 8

Immupharma Plc, History 9

Immupharma Plc, Subsidiaries 14

Immupharma Plc, Key Competitors 22

Immupharma Plc, Ratios based on current share price 23

Immupharma Plc, Annual Ratios 24

Immupharma Plc, Annual Ratios (Cont...1) 25

Immupharma Plc, Interim Ratios 27

Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

Immupharma Plc, Recent Deals Summary 31

Currency Codes 41

Capital Market Ratios 41

Equity Ratios 42

Profitability Ratios 42

Cost Ratios 43

Liquidity Ratios 43

Leverage Ratios 44

Efficiency Ratios 44

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Immupharma Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

ValiRx Plc

Sareum Holdings Plc

Neurocentrx Pharma Ltd

Allergan Ltd

Alcon Laboratories (UK) Ltd

Immupharma Plc (IMM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company's operations and business divisions.

- Corporate strategy - Analyst's summarization of the company's business strategy.

- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history - Progression of key events associated with the company.

- Major products and services - A list of major products, services and brands of the company.

- Key competitors - A list of key competitors to the company.

- Key employees - A list of the key executives of the company.

- Executive biographies - A brief summary of the executives' employment history.

- Key operational heads - A list of personnel heading key departments/functions.

- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities - A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ImmuPharma Plc (ImmuPharma) develops novel drugs for the treatment of serious medical conditions with unmet medical need. ImmuPharma develops drugs for the treatment of lupus, cancer, moderate to severe pain, highly resistant hospital-acquired infections such as methicillin-resistant staphylococcus aureus infection and inflammatory disorders including rheumatoid arthritis and asthma. The company's product pipeline comprises Lupuzor, for the treatment of Lupus; IPP-204106, for the treatment of cancer; and peptide platform for the treatment of metabolic disorders. It has operations in France and Switzerland. ImmuPharma is headquartered in England, the UK.

Immupharma Plc Key Recent Developments

May 29,2018: ImmuPharma: Final Results Announcement for the twelve months ended 31 December 2017

Sep 27,2017: ImmuPharma: Interim Results Announcement for the Six Months Ended 30 June 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1 - About the Company 5

Immupharma Plc - Key Facts 5

Immupharma Plc - Key Employees 6

Immupharma Plc - Key Employee Biographies 7

Immupharma Plc - Major Products and Services 8

Immupharma Plc - History 9

Immupharma Plc - Company Statement 11

Immupharma Plc - Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Section 2 - Company Analysis 15

Company Overview 15

Immupharma Plc - Business Description 16

Immupharma Plc - Corporate Strategy 17

Immupharma Plc - SWOT Analysis 18

SWOT Analysis - Overview 18

Immupharma Plc - Strengths 18

Immupharma Plc - Weaknesses 19

Immupharma Plc - Opportunities 20

Immupharma Plc - Threats 21

Immupharma Plc - Key Competitors 22

Section 3 - Company Financial Ratios 23

Financial Ratios - Capital Market Ratios 23

Financial Ratios - Annual Ratios 24

Performance Chart 26

Financial Performance 26

Financial Ratios - Interim Ratios 27

Financial Ratios - Ratio Charts 28

Section 4 - Company's Lifesciences Financial Deals and Alliances 29

Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

Immupharma Plc, Recent Deals Summary 31

Section 5 - Company's Recent Developments 32

May 29, 2018: ImmuPharma: Final Results Announcement for the twelve months ended 31 December 2017 32

Sep 27, 2017: ImmuPharma: Interim Results Announcement for the Six Months Ended 30 June 2017 39

Section 6 - Appendix 41

Methodology 41

Ratio Definitions 41

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Immupharma Plc, Performance Chart (2013 - 2017) 26

Immupharma Plc, Ratio Charts 28

Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Immupharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30


List Of Table

List of Tables

Immupharma Plc, Key Facts 5

Immupharma Plc, Key Employees 6

Immupharma Plc, Key Employee Biographies 7

Immupharma Plc, Major Products and Services 8

Immupharma Plc, History 9

Immupharma Plc, Subsidiaries 14

Immupharma Plc, Key Competitors 22

Immupharma Plc, Ratios based on current share price 23

Immupharma Plc, Annual Ratios 24

Immupharma Plc, Annual Ratios (Cont...1) 25

Immupharma Plc, Interim Ratios 27

Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

Immupharma Plc, Recent Deals Summary 31

Currency Codes 41

Capital Market Ratios 41

Equity Ratios 42

Profitability Ratios 42

Cost Ratios 43

Liquidity Ratios 43

Leverage Ratios 44

Efficiency Ratios 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Immupharma Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

ValiRx Plc

Sareum Holdings Plc

Neurocentrx Pharma Ltd

Allergan Ltd

Alcon Laboratories (UK) Ltd